Fluoroquinolones in the management of community-acquired pneumonia in primary care

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 11, 2010, Pages 1259-1271

  Wispelwey, Brian ^a   Schafer, Katherine R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

antimicrobial resistance; antimicrobials; community acquired pneumonia; fluoroquinolones; pharmacodynamics; pharmacokinetics; primary care

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; VANCOMYCIN;

ACUTE SINUSITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; AREA UNDER THE CURVE; BLOOD CULTURE; CHLAMYDIAL PNEUMONIA; CHRONIC BRONCHITIS; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CRB 65; CURB 65; DIAGNOSTIC ACCURACY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAM STAINING; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEADACHE; HEALTH PERSONNEL ATTITUDE; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HUMAN; INSOMNIA; KLEBSIELLA PNEUMONIAE INFECTION; LIVER DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; MULTIDRUG RESISTANCE; MYCOPLASMA PNEUMONIA; NAUSEA; NONHUMAN; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SCORING SYSTEM; SPUTUM CULTURE; STAPHYLOCOCCAL PNEUMONIA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URINALYSIS;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; OFLOXACIN; PNEUMONIA, BACTERIAL; PRIMARY HEALTH CARE; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 78349296078     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.110     Document Type: Review

References (82)

1. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
2. Niederman MS, Mandell LA, Anzueto A et al. American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Am. J. Respir. Crit. Care. Med. 163, 1730-1754 (2001).
3. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 20, 820-837 (1998).
4. DeFrances CJ, Podgornik MN. 2004 national hospital discharge survey. Adv. Data 371, 1-20 (2006).
5. Escobar GJ, Fireman BH, Palen TE et al Risk adjusting community-acquired pneumonia hospital outcomes using automated databases. Am. J. Manag. Care 14, 158-166 (2008).
6. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC CASE Mix Programme Database. Crit. Care 10(Suppl. 2), S1 (2006).
7. Stanton M W. Improving Treatment Decisions for Patients with Community-Acquired Pneumonia. Agency for Healthcare Research and Quality, Rockville, MD, USA (2002).
8. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 125, 2140-2145 (2004).
9. Lave JR, Lin JL, Fine MJ, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. Semin. Respir. Crit. Care Med. 20, 189-197 (1999).
10. Waterer GW, Buckingham SC, Kessler LA, Quasney MW, Wunderink RG. Decreasing b-lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001. Chest 124, 519-525 (2003).
11. Whitley CG, Farley MM, Hadler J et al.; for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737 (2003).
12. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 14, 101-107 (2008).
13. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J. Lab. Clin. Med. 143, 269-283 (2004).
14. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin. Microbiol. Infect. 8(Suppl. 2), 1-11 (2002).
15. Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37, 1405-1433 (2003).
16. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31(Suppl. 4), S131-S138 (2000).
17. Roson B, Carratala J, Fernandez-Sabe N et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 164, 502-508 (2004).
18. Arancibia F, Ewig S, Martinez JA et al. Antimicrobial treatment failure in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 162, 154-160 (2000).
19. Bartlett JG, Dowell SF, Mandell LA, File Jr. TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia. Clin. Infect. Dis. 31, 347-382 (2000).
20. Eiland EH, Wargo KA, Hamm W, Hassoun AAM. Analysis of adherence to national nosocomial pneumonia treatment guidelines. Ther. Clin. Risk Manag. 3, 983-988 (2007).
21. Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis. 39, 1642-1650 (2004).
22. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Community-acquired pneumonia recovery in the elderly (CAPRI E): effcacy and safety of moxifoxacin therapy versus that of levofoxacin therapy. Clin. Infect. Dis. 42, 73-81 (2006).
23. De Roux A, Marcos MA, Garcia E et al. Viral community-acquired pneumonia in nonimmunocomprosmied adults. Chest 125, 1343-1351 (2004).
24. Templeton KE, Scheltina SA, van Den Eeden WC, Graffelman AW, van Den Broek PJ, Claas ECJ. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin. Infect. Dis. 41, 345-351 (2005).
25. Benninger M, Segreti J. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J. Fam. Pract. 57, S5-S11 (2008).
26. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am. J. Med. 106, 385-390 (1999).
27. Gotfried MH. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am. J. Med. 111(9 Suppl. 1), 25-29 (2001).
28. Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir. Med. 99(1), 60-65 (2005).
29. Wattanathum A, Chaoprasong C, Nunthapisud P et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 123(5), 1512-1519 (2003).
30. Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients. Clin. Geriatr. Med. 23(3), 515-534 (2007).
31. File TM. Community-acquired pneumonia. Lancet 362, 1991-2001 (2003).
32. Lieberman D, Schlaeffer F, Boldur I et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51, 179-184 (1996).
33. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur. Respir. J. 27, 9-11 (2006).
34. Lim WS, van der Eerden MM, Laing R et al. Defning community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58, 377-382 (2003).
35. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336, 243-250 (1997).
36. Bodi M, Rodriguez A, Sole-Violan J et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin. Infect. Dis. 41, 1709-1716 (2005).
37. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 164, 637-644 (2004).
38. Baum SG, Kaltsas A. Guideline tyranny: primum no nocere. Clin. Infect. Dis. 46, 1879-1880 (2008).
39. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am. J. Med. 118, 259-268 (2005).
40. Carrie AG, Kozyrskyyj AL. Outpatient treatment of community-acquired pneumonia: evolving trends and a focus on fuoroquinolones. Can. J. Clin. Pharmacol. 13, e102-e1 11 (2006).
41. Avelox (moxifoxacin hydrochloride). United States prescribing information. Bayer Pharmaceuticals Corporation, Wayne, NJ, USA (2010).
42. Levaquin (levofoxacin), United States prescribing information. Ortho-McNeil, Raritan, NJ, USA (2009).
43. Factive (gemifoxacin mesylate). United States prescribing information. Oscient Pharmaceuticals Corporation, Waltham, NJ, USA (2008).
44. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community- acquired pneumonia in the outpatient setting. Am. J. Med. 118(7 Suppl. 1), 21-28 (2005).
45. Bhavnani SM, Andes DR. Gemifoxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical effcacy, and safety. Pharmacotherapy 25, 717-740 (2005).
46. Lister PD, Sanders CC. Pharmacodynamics of moxifoxacin, levofoxacin and sparfoxacin. J. Antimicrob. Chemother. 47, 811-818 (2001).
47. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fuoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S127-S135 (2005).
48. Scheld WM. Maintaining fuoroquinolone class effcacy: review of infuencing factors. Emerg. Infect. Dis. 9(1), 1-9 (2003).
49. Oldenholt I, Cars O. Pharmacodynamics of moxifoxacin and levofoxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J. Antimicrob. Chemother. 58, 960-965 (2006).
50. Oncu S. Treatment of community-acquired pneumonia, with special emphasis on gemifoxacin. Ther. Clin. Risk Manag. 3, 441-448 (2007).
51. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifoxacin, levofoxacin, and azithromycin in older adults. Chest 125, 965-973 (2004).
52. Rodvold K, Neuhauser M. Pharmacokinetics and pharmacodynamics of fuoroquinolones. Pharmacotherapy 21, 233s-252s (2001).
53. Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once-daily moxifoxacin into lung tissue at pharmacokinetic steady-state. J. Chemother. 15, 558-562 (2003).
54. Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG. Comparative pharmacodynamics of garenoxacin, gemifoxacin, and moxifoxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clin. Ther. 29, 2685-2689 (2007).
55. Fogarty CM, Greenberg RN, Dunbar L et al. Effectiveness of levofoxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, Phase III clinical trials. Clin. Ther. 23, 425-439 (2001).
56. Lode H, File Jr. TM, Mandell L, Ball P, Pypstra R, Thomas M. 185 Gemifoxacin Study Group. Oral gemifoxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical effcacy and tolerability. Clin. Ther. 24, 1915-1936 (2002).
57. Welte T, Petermann Q, Shurmann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Treatment with sequential intravenousor oral moxifoxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin. Infect. Dis. 41, 1697-1705 (2005).
58. Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifoxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 46, 1746-1754 (2002).
59. Doern GV. Antimicrobial resistance with Streptococcus pneumoniae: much ado about nothing? Semin. Respir. Infect. 16, 177-185 (2001).
60. Doern GV, Richter SS, Miller A et al Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41, 139-148 (2005).
61. Zhanel GG, Roberts D, Waltky A et al Pharmacodynamic activity of fuoroquinolones against ciprofoxacin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 49, 807-812 (2002).
62. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofoxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol Infect. Dis. 51, 31-37 (2005).
63. Ryan RJ, Lindsell C, Sheehan P. Fluoroquinolone resistance during 2000-2005: an observational study. BMC Infect. Dis. 8, 71 (2008).
64. Schafer J, Hovde LB, Simonson D, Rotschafer JC. In vitro pharmacodynamics of moxifoxacin versus levofoxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 frst-step parC mutants, and 1 pump mutant. Diagn. Microbiol. Infect. Dis. 60, 155-161 (2008).
65. Iannini PB. The safety profle of moxifoxacin and other fuoroquinolones in special patient populations. Curr. Med. Res. Opin. 23, 1403-1413 (2007).
66. Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofoxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin. Ther. 27, 1251-1259 (2005).
67. Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofoxacin and cefotaxime combined with ofoxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128, 172-183 (2005).
68. Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri S; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifoxacin vs levofoxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 128, 3398-3406 (2005).
69. Torres A, Garau J, Arvis P et al. Moxifoxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin. Infect. Dis. 46, 1499-1509 (2008).
70. Ball P, File TM, Twynholm M, Henkel T; 061 study group. Effcacy and safety of gemifoxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents 18, 19-27 (2001).
71. File Jr. TM, Schlemmer B, Garau J, Cupo M, Young C; 049 Clinical Study Group. Effcacy and safety of gemifoxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafoxacin. J. Antimicrob. Chemother. 48, 67-74 (2001).
72. Leophonte P, File T, Feldman C. Gemifoxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 98, 708-720 (2004).
73. File Jr. TM, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifoxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J. Antimicrob. Chemother. 60, 112-120 (2007). (Pubitemid 47073284)
74. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofoxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37, 752-760 (2003).
75. Carratala J, Fernandez-Sabe N, Ortega L et al. Outpatient care compared with hospitalization for community-acquired pneumonia. Ann. Intern. Med. 142, 165-172 (2005).
76. Rittenhouse BE, Stinnett AA, Dulisse B et al. An economic evaluation of levofoxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am. J. Manag. Care 6, 381-389 (2000).
77. Ye X, Sikirica V, Schein JR et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofoxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin. Ther. 30, 358-371 (2008).
78. Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifoxacin in standard frst-line therapy in community-acquired pneumonia. Eur. Respir. J. 21, 135-143 (2003).
79. Faich GA, Morganroth J, Whitehouse AB et al. Clinical experience with moxifoxacin in patients with respiratory tract infections. Ann. Pharmacother. 38, 749-754 (2004).
80. Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J. Effcacy of moxifoxacin for treatment of penicillin-, macrolide- and multidrug-resistance Streptococcus pneumoniae in community-acquired pneumonia. Int. J. Clin. Pract. 59, 1253-1259 (2005).
81. Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J. Antimicrob. Chemother. 59, 977-989 (2007).
82. Martin M, Moore L, Quilici S, Decramer M, Simoens S. A cost- effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr. Med. Res. Opin. 24, 737-751 (2008).